EGFR and cancer: Indeed, these intriguing findings shed light on the previously unrecognized role of activated autocrine ACh signaling in driving initial cancer therapy escape, which exposes a therapeutic vulnerability that can be clinically exploited to prolong the efficacy of EGFR-TKI treatment.